Sec Form 4 Filing - Lecault Veronique @ AbCellera Biologics Inc. - 2021-06-09

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Lecault Veronique
2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
Chief Operating Officer
(Last) (First) (Middle)
C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET
3. Date of Earliest Transaction (MM/DD/YY)
06/09/2021
(Street)
VANCOUVER, A1V5Y 0A1
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 06/09/2021 S( 1 )( 2 ) 1,000,000 ( 1 ) D $ 25.5 ( 1 ) 273,630 I See Footnote ( 3 )
Common Shares 1,006,000 D
Common Shares 61,580 I By spouse
Common Shares 7,155,008 I See Footnote ( 4 )
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Lecault Veronique
C/O ABCELLERA BIOLOGICS INC.
2215 YUKON STREET
VANCOUVER, A1V5Y 0A1
X Chief Operating Officer
Signatures
/s/ Tryn Stimart, attorney-in-fact 06/10/2021
Signature of Reporting Person Date
Explanation of Responses:
( 1 )On June 9, 2021, the shares were sold in connection with a private sale transaction at a per share price of $25.50.
( 2 )The sale of the shares reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), to the extent of 23,000 shares, with the purchase by the Reporting Person of 6,000 shares at a price of $20 per share on December 15, 2020, and the purchase by the Reporting Person's spouse of 17,000 shares at a price of $20 per share on December 15, 2020, as reported previously on the Reporting Person's Form 4 filed on December 17, 2020. The Reporting Person has voluntarily disgorged to the Issuer the full amount of the resulting statutory profit calculated pursuant to Section 16(b) of the Exchange Act.
( 3 )These shares are held by Slomo Family Trust. The Reporting Person is a co-trustee of the Slomo Family Trust. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein.
( 4 )These shares are held by Pacific Swell Capital Corp ("Pacific Swell"). The Reporting Person is a director of Pacific Swell and shares voting and dispositive power with respect to the shares held by Pacific Swell. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.